(WWSB) - 35 years ago, a pair of scientists made a discovery that they believed would change Alzheimer’s research forever.

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Leqembi’s rollout has been slowed by bottlenecks related to reimbursement uncertainties, diagnostic test requirements and ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Boosting Brain Protein Levels May Slow Decline from Alzheimer's Sep. 11, 2024 — A study found that new monoclonal antibody drugs for Alzheimer's may slow cognitive impairment through boosting ...

Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.

This year's World Alzheimer's Day campaign aims to address the stigma and discrimination while highlighting global efforts to ...

Researches have helped in detecting the disease in early stages and drugs are now being made available for an effective and ...